Multi-stakeholder paediatric oncology strategy workshop (cancers with anaplastic lymphoma kinase aberrations)

  • Email
  • Help

Details

TitleMulti-stakeholder paediatric oncology strategy workshop (cancers with anaplastic lymphoma kinase aberrations)
Date30/01/2017 - 31/01/2017
LocationEuropean Medicines Agency, London, UK
SummaryThe aim of the European Medicines Agency / ACCELERATE platform's workshop is to review unmet therapeutic needs of children with certain types of cancer and opportunities for targeted paediatric development of innovative anti-cancer medicines. The workshop brings together stakeholders from patient organisations, academia, pharmaceutical industry and regulators. The types of cancers that discussed during the workshop include soft tissue and lymphoid and embryonal neoplasms such as inflammatory myofibroblastic tumour, rhabdomyosarcoma, anaplastic large cell lymphoma and neuroblastoma. Important biological aberrations such as of the anaplastic lymphoma kinase (ALK) occur across these diverse cancers, albeit in small numbers of patients, and represent challenges to address the therapeutic needs of affect paediatric patients.

All documents

Name Language First published Last updated
Agenda: Multi-stakeholder paediatric oncology strategy (ALK-driven diseases) (English only) 2017-01-09  

Media Videos


Registration

  • Participation is by invitaiton only.
  • The ACCELERATE platform is a joint initiative in the area of paediatric oncology by organisations of parents, survivors and their supporters, academic consortia, non-commercial organisations and pharmaceutical companies.

Contact point:

Isabel Perez
isabel.perez@ema.europa.eu